Acquisition by Geiger Uri of 27380 shares of Neuropace subject to Rule 16b-3

NPCE Stock  USD 11.52  0.05  0.44%   
About 53% of Neuropace's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Neuropace stock suggests that some investors are interested at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Neuropace Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Neuropace insider trading alert for grant of stock option rt to buy by Geiger Uri, the corporate stakeholder, on 14th of June 2023. This event was filed by Neuropace Inc with SEC on 2023-06-14. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Neuropace's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Neuropace's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Neuropace Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neuropace Fundamental Analysis

We analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Gross Profit

Gross Profit Comparative Analysis

Neuropace is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Neuropace Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuropace stock to make a market-neutral strategy. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics with similar companies.

Peers

Neuropace Related Equities

FNAParagon 28   3.07   
0%
100.0%
GKOSGlaukos Corp   1.54   
0%
50.0%
KIDSOrthopediatrics Corp   0.81   
0%
26.0%
AORTArtivion   0.10   
0%
3.0%
SRDXSurModics   0.12   
3.0%
0%
CNMDCONMED   0.13   
4.0%
0%
IRMDIradimed   0.34   
11.0%
0%
OFIXOrthofix Medical   0.44   
14.0%
0%
ELMDElectromed   1.06   
34.0%
0%
LUNGPulmonx Corp   1.13   
36.0%
0%
ITGRInteger Holdings   1.22   
39.0%
0%
CVRXCVRx   1.64   
53.0%
0%
ANIKAnika Therapeutics   1.89   
61.0%
0%
NVRONevro Corp   2.41   
78.0%
0%

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope